Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges.

Schadt S, Hauri S, Lopes F, Edelmann MR, Staack RF, Villaseñor R, Kettenberger H, Roth AB, Schuler F, Richter WF, Funk C.

Drug Metab Dispos. 2019 Dec;47(12):1443-1456. doi: 10.1124/dmd.119.088997.

PMID:
31748266
2.

Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics.

McAleer CW, Long CJ, Elbrecht D, Sasserath T, Bridges LR, Rumsey JW, Martin C, Schnepper M, Wang Y, Schuler F, Roth AB, Funk C, Shuler ML, Hickman JJ.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaav1386. doi: 10.1126/scitranslmed.aav1386.

PMID:
31217335
3.

Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia.

Sewing S, Roth AB, Winter M, Dieckmann A, Bertinetti-Lapatki C, Tessier Y, McGinnis C, Huber S, Koller E, Ploix C, Reed JC, Singer T, Rothfuss A.

PLoS One. 2017 Nov 6;12(11):e0187574. doi: 10.1371/journal.pone.0187574. eCollection 2017.

4.

Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling.

Moisan A, Gubler M, Zhang JD, Tessier Y, Dumong Erichsen K, Sewing S, Gérard R, Avignon B, Huber S, Benmansour F, Chen X, Villaseñor R, Braendli-Baiocco A, Festag M, Maunz A, Singer T, Schuler F, Roth AB.

Mol Ther Nucleic Acids. 2017 Mar 17;6:89-105. doi: 10.1016/j.omtn.2016.11.006. Epub 2016 Dec 10.

5.

Use of early phenotypic in vivo markers to assess human relevance of an unusual rodent non-genotoxic carcinogen in vitro.

Boess F, Lenz B, Funk J, Niederhauser U, Bassett S, Zhang JD, Singer T, Roth AB.

Toxicology. 2017 Mar 15;379:48-61. doi: 10.1016/j.tox.2017.01.018. Epub 2017 Feb 5.

PMID:
28174063
6.

Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans.

Atienzar FA, Blomme EA, Chen M, Hewitt P, Kenna JG, Labbe G, Moulin F, Pognan F, Roth AB, Suter-Dick L, Ukairo O, Weaver RJ, Will Y, Dambach DM.

Biomed Res Int. 2016;2016:9737920. Epub 2016 Sep 5. Review.

7.

Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.

Ruiz C, Kustermann S, Pietilae E, Vlajnic T, Baschiera B, Arabi L, Lorber T, Oeggerli M, Savic S, Obermann E, Singer T, Rothschild SI, Zippelius A, Roth AB, Bubendorf L.

PLoS One. 2016 Aug 22;11(8):e0160807. doi: 10.1371/journal.pone.0160807. eCollection 2016.

8.

Establishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide Drugs.

Sewing S, Boess F, Moisan A, Bertinetti-Lapatki C, Minz T, Hedtjaern M, Tessier Y, Schuler F, Singer T, Roth AB.

PLoS One. 2016 Jul 21;11(7):e0159431. doi: 10.1371/journal.pone.0159431. eCollection 2016.

9.

Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro.

Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, Roth AB.

PLoS One. 2016 Jul 7;11(7):e0158674. doi: 10.1371/journal.pone.0158674. eCollection 2016.

10.

Minimizing DILI risk in drug discovery - A screening tool for drug candidates.

Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, Lieven R, Fowler S, Youdim K, Ullah M, Marschmann M, Zihlmann C, Siegrist YM, Cascais AC, Di Lenarda E, Durr E, Schaub N, Ang X, Starke V, Singer T, Alvarez-Sanchez R, Roth AB, Schuler F, Funk C.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):429-37. doi: 10.1016/j.tiv.2015.09.019. Epub 2015 Sep 25.

PMID:
26407524
11.

Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat.

Keirstead ND, Bertinetti-Lapatki C, Knapp D, Albassam M, Hughes V, Hong F, Roth AB, Mikaelian I.

Toxicol Pathol. 2015 Oct;43(7):984-94. doi: 10.1177/0192623315601245. Epub 2015 Sep 8.

PMID:
26353978
12.

Health risks of smoking compared to Swedish snus.

Daniel Roth H, Roth AB, Liu X.

Inhal Toxicol. 2005 Dec 1;17(13):741-8. Review.

PMID:
16195209
13.

Routine admitting methods not grist for patient lawsuits.

Roth AB.

Hosp Admitting Mon. 1983 Apr;2(4):49-51. No abstract available.

PMID:
10259452
14.

Legal aspects of hospital-based groups.

Landau BD, Taubin MJ, Roth AB.

Top Health Care Financ. 1982 Winter;9(2):15-28. No abstract available.

PMID:
7179276
15.

When the patient refuses treatment: some observations and proposals for handling the difficult case.

Roth AB, Wild RA.

St Louis Univ Law J. 1979;23(3):429-45. No abstract available.

PMID:
11661828

Supplemental Content

Support Center